Literature DB >> 10595930

Eotaxin expression in Sephadex-induced lung injury in rats.

R F Guo1, P A Ward, J A Jordan, M Huber-Lang, R L Warner, M M Shi.   

Abstract

The CC chemokine eotaxin is a potent and specific eosinophil chemoattractant. Eosinophil-dependent tissue injury has been shown to contribute to airway inflammation such as that in asthma. In the present study, We investigated eotaxin expression in a rat model of pulmonary inflammation (featuring accumulation of eosinophils) induced by intratracheal instillation of cross-linked dextran beads (Sephadex G200). Intratracheal instillation of 5 mg/kg Sephadex caused a time-dependent eosinophil infiltration into the lung, reaching a peak at 24 hours. Eotaxin mRNA in the lung paralleled the eosinophil influx. Eotaxin protein in bronchoalveolar (BAL) fluids and lung homogenates was shown by Western blot and immunostaining to be maximally expressed by 24 hours. Sephadex-induced lung injury, as measured by (125)I-labeled albumin leakage from the pulmonary vasculature, developed in a time-dependent manner. Intravenous injection of blocking antibody to eotaxin significantly decreased eosinophil infiltration and lung permeability. These data suggest that, in the Sephadex model of lung inflammation, eotaxin up-regulation mediates intrapulmonary accumulation of eosinophils and the development of lung injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595930      PMCID: PMC1866946          DOI: 10.1016/S0002-9440(10)65519-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

Review 1.  Chemokines.

Authors:  B J Rollins
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

2.  Recombinant human eotaxin induces oxygen radical production, Ca(2+)-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein.

Authors:  K Tenscher; B Metzner; E Schöpf; J Norgauer; W Czech
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

3.  Sephadex induced granulomatous reaction in rats.

Authors:  N Buyssens; B Loenders; R van den Bossche; A Herman
Journal:  Exp Toxicol Pathol       Date:  1995-11

4.  Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice.

Authors:  A W Mould; K I Matthaei; I G Young; P S Foster
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

5.  Eotaxin expression and eosinophilic inflammation in asthma.

Authors:  S Mattoli; M A Stacey; G Sun; A Bellini; M Marini
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

6.  Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors.

Authors:  J A Gonzalo; C M Lloyd; L Kremer; E Finger; C Martinez-A; M H Siegelman; M Cybulsky; J C Gutierrez-Ramos
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

Review 7.  Chemokines active on eosinophils: potential roles in allergic inflammation.

Authors:  H Kita; G J Gleich
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

8.  Eotaxin stimulates eosinophil adhesion to human lung microvascular endothelial cells.

Authors:  A Burke-Gaffney; P G Hellewell
Journal:  Biochem Biophys Res Commun       Date:  1996-10-03       Impact factor: 3.575

9.  Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils.

Authors:  P D Ponath; S Qin; D J Ringler; I Clark-Lewis; J Wang; N Kassam; H Smith; X Shi; J A Gonzalo; W Newman; J C Gutierrez-Ramos; C R Mackay
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

10.  Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia.

Authors:  M E Rothenberg; J A MacLean; E Pearlman; A D Luster; P Leder
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.